

Roxanne Toivanen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5155637/publications.pdf>

Version: 2024-02-01

8
papers

328
citations

1684188
5
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

657
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis. <i>European Urology</i> , 2015, 67, 496-503.	1.9	112
2	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018, 74, 562-572.	1.9	80
3	A Preclinical Xenograft Model Identifies Castration-Tolerant Cancer-Repopulating Cells in Localized Prostate Tumors. <i>Science Translational Medicine</i> , 2013, 5, 187ra71.	12.4	50
4	Brief Report: A Bioassay to Identify Primary Human Prostate Cancer Repopulating Cells. <i>Stem Cells</i> , 2011, 29, 1310-1314.	3.2	40
5	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , 2021, 12, 5049.	12.8	33
6	A balancing act: PHLPP2 fine tunes AKT activity and MYC stability in prostate cancer. <i>Journal of Cell Biology</i> , 2019, 218, 1771-1772.	5.2	5
7	Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and meta-analysis. <i>BJU International</i> , 2021, , .	2.5	5
8	Hidden clues in prostate cancer – Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. <i>Cancer Letters</i> , 2022, 524, 182-192.	7.2	3